China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People's Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; tablets, pills, oral liquid, and powder; and traditional Chinese medicine granules … Read more
China Shineway Pharmaceutical Group Limited (CSWYF) - Total Assets
Latest total assets as of June 2025: $10.39 Billion USD
Based on the latest financial reports, China Shineway Pharmaceutical Group Limited (CSWYF) holds total assets worth $10.39 Billion USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
China Shineway Pharmaceutical Group Limited - Total Assets Trend (2015–2024)
This chart illustrates how China Shineway Pharmaceutical Group Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
China Shineway Pharmaceutical Group Limited - Asset Composition Analysis
Current Asset Composition (December 2024)
China Shineway Pharmaceutical Group Limited's total assets of $10.39 Billion consist of 85.6% current assets and 14.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 61.2% |
| Accounts Receivable | $1.20 Billion | 12.0% |
| Inventory | $813.19 Million | 8.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $23.32 Million | 0.2% |
| Goodwill | $165.96 Million | 1.7% |
Asset Composition Trend (2015–2024)
This chart illustrates how China Shineway Pharmaceutical Group Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: China Shineway Pharmaceutical Group Limited's current assets represent 85.6% of total assets in 2024, an increase from 62.4% in 2015.
- Cash Position: Cash and equivalents constituted 61.2% of total assets in 2024, up from 46.6% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 11.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 12.0% of total assets.
China Shineway Pharmaceutical Group Limited Competitors by Total Assets
Key competitors of China Shineway Pharmaceutical Group Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
China Shineway Pharmaceutical Group Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - China Shineway Pharmaceutical Group Limited generates 0.38x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, China Shineway Pharmaceutical Group Limited generates $8.37 in net profit.
China Shineway Pharmaceutical Group Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.69 | 3.48 | 4.09 |
| Quick Ratio | 3.39 | 3.14 | 3.77 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.52 Billion | $ 829.75 Million | $ 598.22 Million |
China Shineway Pharmaceutical Group Limited - Advanced Valuation Insights
This section examines the relationship between China Shineway Pharmaceutical Group Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.73 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 644.1% |
| Total Assets | $10.04 Billion |
| Market Capitalization | $207.87 Million USD |
Valuation Analysis
Below Book Valuation: The market values China Shineway Pharmaceutical Group Limited's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: China Shineway Pharmaceutical Group Limited's assets grew by 644.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for China Shineway Pharmaceutical Group Limited (2015–2024)
The table below shows the annual total assets of China Shineway Pharmaceutical Group Limited from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $10.04 Billion | +644.06% |
| 2023-12-31 | $1.35 Billion | +14.07% |
| 2022-12-31 | $1.18 Billion | +4.70% |
| 2021-12-31 | $1.13 Billion | +2.45% |
| 2020-12-31 | $1.10 Billion | +7.74% |
| 2019-12-31 | $1.02 Billion | +4.41% |
| 2018-12-31 | $980.50 Million | -4.20% |
| 2017-12-31 | $1.02 Billion | +10.02% |
| 2016-12-31 | $930.32 Million | -1.82% |
| 2015-12-31 | $947.56 Million | -- |